MedTrace Logo

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

NCT07244406 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-11-24

No results posted yet for this study

Summary

To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.

Conditions

  • B-ALL

Interventions

BIOLOGICAL

S1904 CD19 CAR-T

Autologous CD19-targeting CAR T cells

Sponsors & Collaborators

  • Hebei Senlang Biotechnology Inc., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaojun Huang · Peking University People's Hospital

  • Hongsheng Zhou · Nanfang Hospital, Southern Medical University

  • Ruidong Zhang · Beijing Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2027-03-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07244406 on ClinicalTrials.gov